Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
Aiolos
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "Aiolos" in MCE Product Catalog:
1
Research Areas:
Zomiradomide (KT-413) is an orally active IRAK4 PROTAC degrader with a DC50 of 6 nM. Zomiradomide inhibits the NF-κB signaling pathway, while its molecular glue function mediates the degradation of Ikaros and Aiolos (with a DC50 of 1 nM for both), activates the IFN-I signaling pathway, and selectively degrades IMiD substrates. Zomiradomide inhibits cancer cell proliferation and tumor growth. Zomiradomide can be used in research related to B-cell non-Hodgkin's lymphoma and diffuse large B-cell lymphoma .
Synonyms: CC-99282
Research Areas:
Golcadomide (CC-99282) is a blood-brain barrier-permeable, orally active Cereblon (CRBN) E3 ligase modulator. Golcadomide induces Cereblon to form a closed active conformation, thereby recruiting and triggering the ubiquitin-mediated proteasomal degradation of transcription factors IKZF1, IKZF3, Ikaros and Aiolos. Golcadomide is applicable to research related to relapsed or refractory non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and diffuse large B-cell lymphoma .
Synonyms: CFT7455
Target:
Research Areas:
Cemsidomide (CFT7455) is a ubiquitin ligase pathway based IKZF1/3 (Ikaros/Aiolos) degrader with molecular glue activity . Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells. Cemsidomide is used in the research of multiple myeloma (MM) .
KTX-951 is an orally active PROTAC degrader of IRAK4 and IMiD (Ikaros/Aiolos) substrates (Kd = 3.5 nM). KTX-951 induces IRAK4 degradation, and the degradation efficiency is independent of IRAK4 binding affinity. The DC50 values of KTX-951 for IRAK4, Ikaros and Aiolos are 18 nM, 14 nM and 13 nM, respectively. The IC50 of KTX-951 against OCl-Ly10 CTG is 35 nM. KTX-951 exhibits antitumor activity .
Cat. No.: HY-RS06667
Target:
Research Areas:
IKZF3 Human Pre-designed siRNA Set A contains three designed siRNAs for IKZF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS17040
Target:
Research Areas:
Ikzf3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ikzf3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-144983
CAS No.: 2377849-57-3
Target:
Research Areas:
E3 ligase Ligand 22 (compound 139) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .
Synonyms: (Rac)-CFT7455
Target:
Research Areas:
(Rac)-Cemsidomide ((Rac)-CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity . Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells.
Cat. No.: HY-144980
CAS No.: 2504233-73-0
Target:
Research Areas:
E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .
Target:
Research Areas:
E3 ligase Ligand 23 (compound 17-6) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .
Cat. No.: HY-189947
Target:
Research Areas:
HDAC4-IN-3 is a class IIa HDAC4 inhibitor. HDAC4-IN-3 disrupts the HDAC4-JunB transcriptional complex, thereby blocking HDAC4 cooperation with JunB to activate Th17 signature genes, and disrupts HDAC4-JunB interactions in Th17 cells with no detectable effect on HDAC7-Aiolos binding .
Cat. No.: HY-W1128734
CAS No.: 2259852-44-1
Target:
Research Areas:
Piperidine-2,6-dione-NH-pyridine-piperazine (compound 158) is an E3 ubiquitin ligase binding agent. Piperidine-2,6-dione-NH-pyridine-piperazine enhances the interaction with Ikaros and Aiolos, inducing their ubiquitination and degradation .
Cat. No.: HY-189948
Target:
Research Areas:
HDAC4/HDAC7-IN-1 is a TMP269 (HY-18360)-derived HDAC4/HDAC7 selective inhibitor. HDAC4/HDAC7-IN-1 selectively inhibits HDAC7-dependent transcription relative to HDAC4-dependent transcription. HDAC4/HDAC7-IN-1 selectively disrupts the HDAC7-Aiolos protein interaction but does not interfere with the HDAC4-JunB complex.=HDAC4/HDAC7-IN-1 can be used for research on HDAC4/HDAC7-mediated related diseases, such as inflammatory diseases .
Cat. No.: HY-W947273
CAS No.: 2766178-72-5
Target:
Research Areas:
CRBN ligand-898 is a CRBN ligand with a Kd of 216 nM. CRBN ligand-898 binds to CRBN, and when incorporated into proteolysis targeting chimeras (PROTACs), mediates degradation of intended target proteins. CRBN ligand-898 does not induce degradation of IMiD-associated neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). CRBN ligand-898 can be used to synthesize PROTACs .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
